© 2005 Oxford University Press
ARTICLE |
Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
Affiliations of authors: Università "La Sapienza," Rome, Italy (PBP, NM); Istituto Europeo di Oncologia, Milan, Italy (AM, FL); Royal Hospital for Women, Randwick, Australia (NH); University of Erlangen-Nuremberg, Erlangen, Germany (SA); Centro di Riferimento Oncologico, Aviano, Italy (EC, LM); Medical University of Graz, Graz, Austria (KT, RW); S. Gerardo Hospital, Monza, Italy (AP, TD, RSR, CM); Istituto Nazionale Tumori, Fondazione G. Pascale, Naples, Italy (SG); Università "Campus Biomedico," Rome, Italy (RA); Università Cattolica del "Sacro Cuore," Rome, Italy (GS); Laboratory of Clinical Cancer Research, Mario Negri Institute, Milan, Italy (RF, IF); Treviglio Hospital, Treviglio, Italy (RG); Spedali Civili di Brescia, Brescia, Italy (GF); Istituto Nazionale Tumori, Milan, Italy (FR); IFO-Istituto Regina Elena, Rome, Italy (DG)
Correspondence to: Roldano Fossati, MD, Istituto Mario Negri, Via Eritrea 62, 20157, Milan, Italy (e-mail: fossati{at}marionegri.it).
Background: The role of systematic aortic and pelvic lymphadenectomy in patients with optimally debulked advanced ovarian cancer is unclear and has not been addressed by randomized studies. We conducted a randomized clinical trial to determine whether systematic aortic and pelvic lymphadenectomy improves progression-free and overall survival compared with resection of bulky nodes only. Methods: From January 1991 through May 2003, 427 eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-C and IV epithelial ovarian carcinoma were randomly assigned to undergo systematic pelvic and para-aortic lymphadenectomy (n = 216) or resection of bulky nodes only (n = 211). Progression-free survival and overall survival were analyzed using a log-rank statistic and a Cox multivariable regression analysis. All statistical tests were two-sided. Results: After a median follow-up of 68.4 months, 292 events (i.e., recurrences or deaths) were observed, and 202 patients had died. Sites of first recurrences were similar in both arms. The adjusted risk for first event was statistically significantly lower in the systematic lymphadenectomy arm (hazard ratio [HR] = .75, 95% confidence interval [CI] = 0.59 to 0.94; P = .01) than in the no-lymphadenectomy arm, corresponding to 5-year progression-free survival rates of 31.2 and 21.6% in the systematic lymphadenectomy and control arms, respectively (difference = 9.6%, 95% CI = 1.5% to 21.6%), and to median progression-free survival of 29.4 and 22.4 months, respectively (difference = 7 months, 95% CI = 1.0 to 14.4 months). The risk of death was similar in both arms (HR = 0.97, 95% CI = 0.74 to 1.29; P = .85), corresponding to 5-year overall survival rates of 48.5 and 47%, respectively (difference = 1.5%, 95% CI = –8.4% to 10.6%), and to median overall survival of 58.7 and 56.3 months, respectively (difference = 2.4 months, 95% CI = –11.8 to 21.0 months). Median operating time was longer, and the percentage of patients requiring blood transfusions was higher in the systematic lymphadenectomy arm than in the no-lymphadenectomy arm (300 versus 210 minutes, P<.001, and 72% versus 59%; P = .006, respectively). Conclusion: Systematic lymphadenectomy improves progression-free but not overall survival in women with optimally debulked advanced ovarian carcinoma.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
- Philippe Morice, Patricia Pautier, Catherine Lhommé, and Damienne Castaigne
J Natl Cancer Inst 2005 97: 1620-1621.[Extract] [Full Text] [PDF]
- Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
- Denis Querleu and Gwenael Ferron
J Natl Cancer Inst 2005 97: 1621.[Extract] [Full Text] [PDF]
Editorial about this Article
- Systematic Lymphadenectomy in Advanced Epithelial Ovarian Cancer: Two Decades of Uncertainty Resolved
- Setsuko K. Chambers
J Natl Cancer Inst 2005 97: 548-549.[Extract] [Full Text] [PDF]
Related Memo to the Media
- Press Release: No Improvement in Overall Survival With Lymph Node Removal in Treatment of Advanced Ovarian Cancer
- Sarah L. Zielinski
J Natl Cancer Inst 2005 97: 547.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  O. CAMARA and J. SEHOULI Controversies in the Management of Ovarian Cancer - Pros and Cons for Lymph Node Dissection in Ovarian Cancer Anticancer Res, July 1, 2009; 29(7): 2837 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zivanovic, F. Khoury-Collado, N. R. Abu-Rustum, and M. L. Gemignani Sentinel Lymph Node Biopsy in the Management of Vulvar Carcinoma, Cervical Cancer, and Endometrial Cancer Oncologist, July 1, 2009; 14(7): 695 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Kim, N.-H. Park, H. H. Chung, J. W. Kim, Y.-S. Song, and S.-B. Kang Are Three Additional Cycles of Chemotherapy Useful in Patients with Advanced-stage Epithelial Ovarian Cancer After a Complete Response to Six Cycles of Intravenous Adjuvant Paclitaxel and Carboplatin? Jpn. J. Clin. Oncol., June 1, 2008; 38(6): 445 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Prat, M. Parera, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, I. Roxana, J. Baselga, and J. M. Del Campo Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer Ann. Onc., February 1, 2008; 19(2): 327 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Fader and P. G. Rose Role of Surgery in Ovarian Carcinoma J. Clin. Oncol., July 10, 2007; 25(20): 2873 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Crawford, J. Paul, S. B. Kaye, P. A. Vasey, J. A. Davis, and A. Hay In Reply: J. Clin. Oncol., May 20, 2006; 24(15): 2398 - 2399. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Crawford, P. A. Vasey, J. Paul, A. Hay, J. A. Davis, and S. B. Kaye Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial J. Clin. Oncol., December 1, 2005; 23(34): 8802 - 8811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Morice, P. Pautier, C. Lhomme, and D. Castaigne Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial J Natl Cancer Inst, November 2, 2005; 97(21): 1620 - 1621. [Full Text] [PDF]
|
|
|
|
|
|
D. Querleu and G. Ferron Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial J Natl Cancer Inst, November 2, 2005; 97(21): 1621 - 1621. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Chambers, D. S. Alberts, and K. D. Hatch RESPONSE: Re: Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial J Natl Cancer Inst, November 2, 2005; 97(21): 1622 - 1623. [Full Text] [PDF]
|
|
|
|
|
|
S. K. Chambers Systematic Lymphadenectomy in Advanced Epithelial Ovarian Cancer: Two Decades of Uncertainty Resolved J Natl Cancer Inst, April 20, 2005; 97(8): 548 - 549. [Full Text] [PDF]
|
|